2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1931

Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNAseq
Abstract Number: 1041

Computational Methods for Drug Repositioning of Systemic Sclerosis Using Gene Fold-Change and Network Analyses
Abstract Number: 2590

Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis
Abstract Number: 243

Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment
Abstract Number: 1537

Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study
Abstract Number: 429

Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results
Abstract Number: 1309

Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis
Abstract Number: 977

Conditional Deletion of MKL1 Inhibits Osteoclast Formation and Bone Erosions in Collagen Induced Arthritis Mice
Abstract Number: 1180

Confirmation of Manual Cartilage Segmentation Findings by Automated Segmentation: Retrospective Analysis of MRI Images from a Sprifermin Phase II Study
Abstract Number: 1391

Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study
Abstract Number: 2386

Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Abstract Number: 1365

Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States
Abstract Number: 2191

Construct Validity of OMERACT Ultrasound Knee Scores with Pain, Other Symptoms, Radiographic and MRI Findings
Abstract Number: 2523

Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1818

Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].